All In Biotech

Drug Trial Radar · NCT03372161

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)

Last checked: Nov 19, 2026Latest source record: Sep 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

401

Actual

Start

Dec 8, 2017

Primary completion

Aug 20, 2021

Study completion Jan 6, 2022

Sponsor

Lead sponsor
Scilex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; Semnur Pharmaceuticals, Inc.
First posted
Dec 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The medication is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment. The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain. The study will also investigate the side effects of SP-102.

Conditions

  • Lumbosacral Radicular Pain

Interventions

  • SP-102Drug

    injection

  • PlaceboDrug

    injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (Day 1) to Week 4 in the Mean Numeric Pain Rating Scale (NPRS) Average Pain Score in the Affected LegTime frame: Baseline, 4 Weeks

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • Semnur Research Site 75

    Mobile, Alabama

  • Semnur Research Site 52

    Phoenix, Arizona

  • Semnur Research Site 58

    Tempe, Arizona

  • Semnur Research Site 18

    La Jolla, California

  • Semnur Research Site 47

    Laguna Woods, California

  • Semnur Research Site 70

    Los Gatos, California

  • Semnur Research Site 56

    Fernandina Beach, Florida

  • Semnur Research Site 81

    Jacksonville, Florida

  • Semnur Research Site 49

    St. Petersburg, Florida

  • Semnur Research Site 13

    Tampa, Florida

  • Semnur Research Site 61

    Tampa, Florida

  • Semnur Research Site 53

    Winter Park, Florida

  • Semnur Research Site 28

    Marietta, Georgia

  • Semnur Research Site 64

    Marietta, Georgia

  • Semnur Research Site 10

    Newnan, Georgia

  • Semnur Research Site 38

    Boise, Idaho

  • Semnur Research Site 40

    Bloomington, Illinois

  • Semnur Research Site 63

    Chicago, Illinois

  • Semnur Research Site 12

    Chicago, Illinois

  • Semnur Research Site 19

    Chicago, Illinois

  • Semnur Reseach Site 62

    Overland Park, Kansas

  • Semnur Research Site 51

    Burlington, Massachusetts

  • Semnur Research Site 65

    Omaha, Nebraska

  • Semnur Research Site 60

    Las Vegas, Nevada

  • Semnur Research Site 30

    Shrewsbury, New Jersey

  • Semnur Research Site 11

    Durham, North Carolina

  • Semnur Research Site 20

    Winston-Salem, North Carolina

  • Semnur Research Site 46

    Cleveland, Ohio

  • Semnur Research Site 43

    Cuyahoga Falls, Ohio

  • Semnur Research Site 36

    Oklahoma City, Oklahoma

  • Semnur Research Site 48

    Charleston, South Carolina

  • Semnur Research Site 77

    Greenville, South Carolina

  • Semnur Research Site 15

    Houston, Texas

  • Semnur Research Site 54

    Plano, Texas

  • Semnur Research Site 35

    Tyler, Texas

  • Semnur Research Site 59

    Draper, Utah

  • Semnur Research Site 42

    Greenfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.